AGN News and Press, Allergan plc From 02/10/20

U.S. stock index futures were little changed on Monday as investors assess the economic impact of the coronavirus outbreak in China. Futures for the Dow Jones Industrials dropped 31 points, or 0.1%, early Friday to 29,015. Futures for the S&P 500 sank 1.75 points, or 0.1%, at 3,32...

Allergan ( AGN ) Q4 results : More news on: Allergan plc, Healthcare stocks news, Earnings news and commentary, Read more ...

Allergan (NYSE: AGN ): Q4 Non-GAAP EPS of $5.22 beats by $0.69 ; GAAP EPS of -$0.97 misses by $1.48 . More news on: Allergan plc, Earnings news and commentary, Healthcare stocks news, Read more ...

DUBLIN , Feb. 10, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) today reported its full-year and fourth quarter 2019 financial results including full-year 2019 GAAP net revenues of $16.1 billion , a 1.9 percent increase from 2018. Fourth quarter 2019 GAAP net revenues were $4.35...

AbbVie (NYSE: ABBV) hasn't been delivering the kind of stock performance that investors like. But the drugmaker continues to beat expectations with its financial results. In November, the company reported a surprisingly solid performance with its third-quarter results. And now AbbVie has d...

Jefferies' Michael Yee says investors believe that Gilead Sciences ( GILD +0.6% ) is an acquisition target considering its near-term share performance (at the same level as three years ago with some volatility thrown in) and tepid growth prospects (little or no topline increase expected th...

A new alternative to Allergan 's (NYSE: AGN) blockbuster aesthetics treatment Botox may be available by the end of 2020. On Thursday,  Revance Therapeutics (NASDAQ: RVNC)  announced the Food and Drug Administration (FDA) accepted its application for approval of DAXI (daxibotulinum...

Revance Therapeutics (NASDAQ: RVNC ) has filed a marketing application in the U.S. seeking approval of DAXI (daxibotulinumtoxinA for injection) for the treatment of moderate-to-severe glabellar (frown) lines. The agency's action date is November 25. More news on: Revance Therapeutics, In...

Musings January 2020 was a tough month for stocks but was especially tough for value and international (especially emerging markets). Source: S&P Dow Jones Source: S&P Dow Jones I hate to dwell on the ugly, but things were really ugly for domestic energy stocks as w...

Source (Shutterstock/Liya Graphics) Introduction Gilead Sciences ( GILD ) was positioned to be the poster child of Trump's plan to eradicate HIV, as outlined in my previous article . Like almost all outbreaks including the Wuhan coronavirus, the only effective way to complete...